First, MHRA has explicitly stated that the DCVax-L application is not in backlog and is not delayed. So you can try to beat a dead horse, but the facts are clearly not in your favor.
This clarification matters. It means the review is proceeding within expected parameters for a complex, personalized therapy—contrary to any narrative that suggests Northwest Bio is simply “being slow.”
1. DCVax-L Is a First-of-Its-Kind Therapy
Yes, other dendritic cell (DC) vaccines have existed—and yes, Car-T therapies are complex—but DCVax-L represents an entirely new category in cancer immunotherapy, particularly for solid tumors like glioblastoma.
Here’s how it’s different:
• Fully Personalized: Each dose is created using a patient’s own tumor lysate to train autologous dendritic cells. This goes far beyond using predefined tumor antigens or shared neoantigens.
• For Solid Tumors: Unlike most cell therapies (including Car-Ts) which target blood cancers, DCVax-L is designed to function in the highly immunosuppressive environment of glioblastoma—a major technical and biological hurdle.
• Clinical Validation: It is supported by a large, placebo-controlled phase 3 trial published in JAMA Oncology, showing a statistically significant survival benefit. That scale of evidence is rare for personalized immunotherapies.
This is not a tweak on an existing model—it’s a fundamental shift in how immunotherapy can be personalized and delivered in solid tumors.
2. Why the Regulatory Process Deserves Nuance
The assertion that “MHRA is on time and NWBO is slow” oversimplifies and misplaces the issue:
• Regulatory bodies like the MHRA adapt their review process depending on a therapy’s complexity, manufacturing model, and risk profile.
• Unlike conventional drugs or even standardized cell therapies, DCVax-L requires validation of:
• Patient-specific tumor lysate processing
• Sterility and safety for hundreds of unique cell batches
• Consistency in manufacturing despite biological variability
• This scrutiny is expected for something so novel—and it reflects regulatory diligence, not company missteps.
Furthermore, MHRA’s own communication clarifies there is no backlog or delay, making the claim that NWBO is the hold-up factually incorrect.
3. Car-T and Other DC Therapies Are Not Equivalents
While the MHRA has approved advanced therapies like Car-T for sickle cell disease, those approvals:
• Involved well-characterized, repeatable targets like CD19 or BCMA
• Used standardized manufacturing protocols across patients
• Were typically backed by large pharma with robust submission infrastructures
DCVax-L differs:
• Each batch is biologically distinct due to the patient-specific tumor lysate
• Its target is not one antigen, but a broad, undefined array of patient-specific tumor signals
• NWBO, a small biotech, conducted a rigorous clinical trial and has had to build regulatory pathways for a therapy with no exact precedent
This comparison is apples to oranges in both technical and regulatory terms.
Conclusion:
DCVax-L is the first therapy of its kind—not just a dendritic cell vaccine, but a fully individualized, autologous treatment for one of the most challenging cancers in medicine. That demands careful review.
And MHRA has affirmed: there’s no delay. The process is proceeding on track, with appropriate diligence. That’s not a red flag—it’s the system working responsibly to evaluate a genuinely innovative treatment.
I had AI clean up my actual rebuttal, but just to be clear... these are my points.
Market Data 
Markets 
